About YM BioSciences
YM BioSciences is a life sciences product development company advancing a diverse portfolio of hematology and cancer-related products at various stages of development. In February 2013, YM BioSciences was acquired by Gilead Sciences. The valuation of YM BioSciences was undisclosed. Other terms of the deal were not released.
YM BioSciences Patents
YM BioSciences has filed 15 patents.
Monoclonal antibodies, Small nuclear RNA, Clusters of differentiation, Immune system, Immunology
Monoclonal antibodies, Small nuclear RNA, Clusters of differentiation, Immune system, Immunology
Latest YM BioSciences News
Oct 14, 2022
Search jobs 14-Oct-2022 Chronic Idiopathic Myelofibrosis Market See the List of Gartner Analysis Study With YM BioSciences and Sanofi, Market.us Pune, Maharashtra, India, October 14 2022 (Wiredrelease) Prudour Pvt. Ltd –:Chronic idiopathic myelofibrosis (CIMF) is a rare, progressive blood disorder in which the bone marrow is infiltrated by fibrous tissue. This results in decreased production of normal blood cells, leading to anemia, fatigue, and an increased risk of infection. There is currently no cure for CIMF, and treatment options are limited. The CIMF market is expected to grow significantly in the next decade due to the increasing incidence of the disease and the lack of effective treatments. Current treatments are only able to manage symptoms and do not provide a cure. With the development of new therapies, the CIMF market is expected to grow significantly. Competitive Spectrum – Top Companies Participating in the Chronic Idiopathic Myelofibrosis Market are: S-BIO 1. New Investors 3. Cautious business organizers and analysts 4. Intelligent network security Suppliers, Manufacturers and Distributors 5. Government and research organizations 6. Speculation / Business Research League 7. End-use industries And much more Chronic Idiopathic Myelofibrosis Market Segments Evaluated in the Report: Product Overview: Hospitals Key regions divided during this report: – The Middle East and Africa Chronic Idiopathic Myelofibrosis Market (Saudi Arabia, United Arab Emirates, Egypt, Nigeria, South Africa) – North America Chronic Idiopathic Myelofibrosis Market (United States, Canada, Mexico) – Asia Pacific Chronic Idiopathic Myelofibrosis Market (China, Japan, Korea, India, Southeast Asia) – South America Chronic Idiopathic Myelofibrosis Market (Brazil, Argentina, Colombia) – Europe Chronic Idiopathic Myelofibrosis Market (Germany, UK, France, Russia, Italy) Click the link if you are planning to make a direct purchase @ https://market.us/purchase-report/?report_id=47445 The Chronic Idiopathic Myelofibrosis market research is sourced for experts in both primary and developed statistics and includes qualitative and quantitative details. The analysis is derived from Manufacturers’ experts work around the clock to recognize current circumstances, such as COVID-19, the possible financial reversal, the impact of a trade slowdown, the importance of the limitation on export and import, and all the other factors that may increase or decrease market growth during the forecast period. TOC Highlights: Chapter 1. Introduction The Chronic Idiopathic Myelofibrosis research work report covers a brief introduction to the global market. this segment provides opinions of key participants, an audit of Chronic Idiopathic Myelofibrosis industry, an outlook across key regions, financial services and various challenges faced by Chronic Idiopathic Myelofibrosis Market. This section depends on the Scope of the Study and Report Guidance. Chapter 2. Outstanding Report Scope This is the second most important chapter, which covers market segmentation along with a definition of Chronic Idiopathic Myelofibrosis. It defines the entire scope of the Chronic Idiopathic Myelofibrosis report and the various facets it is describing. Chapter 3. Market Dynamics and Key Indicators This chapter includes key dynamics focusing on drivers[ Includes Globally Growing Chronic Idiopathic Myelofibrosis Prevalence and Increasing Investments in Chronic Idiopathic Myelofibrosis, Key Market Restraints [High Cost of Chronic Idiopathic Myelofibrosis], opportunities [Emerging Markets in Developing Countries] and also presented in detail the emerging trends [Consistent Launch of New Screening Products] growth challenges, and influence factors shared in this latest report. Chapter 4. Type Segments This Chronic Idiopathic Myelofibrosis market report shows the market growth for various types of products marketed by the most comprehensive companies. Chapter 5. Application Segments The examiners who wrote the report have fully estimated the market potential of key applications and recognized future opportunities. Chapter 6. Geographic Analysis Each regional market is carefully scrutinized to understand its current and future growth, development, and demand scenarios for this market. 7.1 North America: Insight On COVID-19 (Omicron) Impact Study 2021 7.2 Europe: Serves Complete Insight On COVID-19 (Omicron) Impact Study 2021 7.3 Asia-Pacific: Potential Impact of COVID-19 (Omicron) 7.4 Rest of the World: Impact Assessment of COVID-19 (Omicron) Pandemic Chapter 8. Manufacturing Profiles The major players in the Chronic Idiopathic Myelofibrosis market are detailed in the report based on their market size, market service , products, applications, regional growth, and other factors. Chapter 9. Pricing Analysis Chapter 10. North America Chronic Idiopathic Myelofibrosis Market Analysis This chapter includes an assessment of Chronic Idiopathic Myelofibrosis product sales across major countries of the United States and Canada along with a detailed segmental outlook across these countries for the forecasted period 2022-2031. Chapter 11. Latin America Chronic Idiopathic Myelofibrosis Market Analysis Major countries of Brazil, Chile, Peru, Argentina, and Mexico are assessed apropos to the adoption of Chronic Idiopathic Myelofibrosis. Chapter 12. Europe Chronic Idiopathic Myelofibrosis Market Analysis Market Analysis of Chronic Idiopathic Myelofibrosis report includes insights on supply-demand and sales revenue of Chronic Idiopathic Myelofibrosis across Germany, France, United Kingdom, Spain, BENELUX, Nordic and Italy. Chapter 13. Asia Pacific Excluding Japan (APEJ) Chronic Idiopathic Myelofibrosis Market Analysis Countries of Greater China, ASEAN, India, and Australia & New Zealand are assessed and sales assessment of Chronic Idiopathic Myelofibrosis in these countries is covered. Chapter 14. The Middle East and Africa (MEA) Chronic Idiopathic Myelofibrosis Market Analysis This chapter focuses on Chronic Idiopathic Myelofibrosis market scenario across GCC countries, Israel, South Africa, and Turkey. Chapter 15. Research Methodology 15.1 Coverage
YM BioSciences Frequently Asked Questions (FAQ)
When was YM BioSciences founded?
YM BioSciences was founded in 1994.
Where is YM BioSciences's headquarters?
YM BioSciences's headquarters is located at 5045 Orbitor Drive, Mississauga.
What is YM BioSciences's latest funding round?
YM BioSciences's latest funding round is Acq - P2P.
Who are the investors of YM BioSciences?
Investors of YM BioSciences include Gilead Sciences and New Enterprise Associates.
Who are YM BioSciences's competitors?
Competitors of YM BioSciences include Cerecin, Panacea Pharmaceuticals, Titan Pharmaceuticals, Keryx Biopharmaceuticals, Orexigen Therapeutics and 7 more.
Compare YM BioSciences to Competitors
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
AngioChem is a clinical-stage biotechnology discovering and developing drugs that are capable of crossing the blood-brain barrier to treat brain diseases. The company's EPiC platform aims to solve the key problem for crossing the blood-brain barrier by developing drugs that use a receptor-based approach.
Galenea is a biopharmaceutical company discovering and developing drugs to treat schizophrenia and other central nervous system diseases. The company has developed technology, the MANTRA (Multiwell, Automated NeuroTRansmission Assay) system, which enables direct high throughput screening of synaptic function in cultured primary neurons from mice and rats, and in neurons derived from human induced pluripotent stem cells. The company is using the MANTRA system to characterize synaptic dysfunctions in disease models and to identify signatures of therapeutic compound classes.
Edunn Biotechnology, Inc. is developing oligonucleotide drugs to treat central nervous system diseases. The company currently has two drugs in development. Edunn's OL-1 drug is designed to cure Alzheimer's disease and to treat Down syndrome. Per the company, it is highly selective and has shown significant activity and safety in multiple preclinical models. The company's OL-202 would be used to treat stroke and traumatic brain injury.
Targeson is a biotechnology company that develops, manufactures, and markets ultrasound contrast agent technologies for pre-clinical molecular imaging in animal models. Targeson is also developing this technology for site-specific diagnosis and therapy in humans. The company has engineered a versatile microparticle platform that may be used as both a contrast agent and, in a slightly modified form, a drug or gene delivery agent. Targeson manufactures and sells the Targestarline of contrast agents for ultrasound-based molecular and functional imaging in animal models of disease. Targeson's agents can be readily targeted to the molecular signature of many diseases, and can be used to detect pathophysiology on the molecular level. The company's intellectual property aims to enable the agents to bind with high efficiency to the intended molecular targets. In addition, the company is investigating therapeutic technology for simultaneous imaging and delivery, which aims to enable the user to verify that the therapeutic compound has been delivered to the intended site.
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.